GLP-1s: 2024 Clinical Insights An Update on Payer Strategies, New Indications & Drugs in the Pipeline

GLP-1s: 2024 Clinical Insights An Update on Payer Strategies, New Indications & Drugs in the Pipeline

A must-read for payers, employers & benefit consultants on the future of weight loss drugs

 

In 2023, weight loss drugs captured the public’s attention like never before, with GLP-1 agonists such as Ozempic, Wegovy, Saxenda and Mounjaro leading the conversation.

Beyond their weight loss benefits, this class of drugs has recently begun to make waves for new cardiac indications, broadening their potential impact on public health and payer budgets.

Our latest guide provides critical clinical updates on: 

  • New players in the weight loss medication space
  • Insights and payer trends: will coverage expand in 2024?
  • The long-term impact and costs of GLP-1 weight loss therapies, and more!

Please note: This is an update to our 2023 guide, “Balancing the Scales: A Comprehensive Guide for Healthcare Payers on the Value and Viability of New Weight Loss Medications”

Download the Report Today!


Featured Company
Focus Areas
  • Reducing Pharmacy Costs
  • Removing Cost Barriers
Experts In This Article

Nick McLaughlin
CEO, Breeze

Share
Featuring Solutions For
Custom CTA designs for this insight
Get the latest digital download or fill out our contact form to talk to an expert about this type of content. This module is optional and meant to allow Insight pages to act as landing pages when appropriate contact form
Related Insights
Break up with the status quo

We’re igniting real change. From building and accelerating revolutionary healthcare businesses to delivering transformative tech and services to our clients, we’re raising the bar of what healthcare can be.

Ready to join us?